Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Gainers
Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84 million.
Where Reata Pharmaceuticals Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review
Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients with Friedreich's ataxia.
The Daily Biotech Pulse: Setback For NRx Pharma’s COVID Study, Fast Track Tag For Pfizer’s NASH Combo Therapy, Reata’s Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours:
Goldman Sachs Maintains Buy on Reata Pharmaceuticals, Lowers Price Target to $73
Goldman Sachs analyst Madhu Kumar maintains Reata Pharmaceuticals (NASDAQ:RETA) with a Buy and lowers the price target from $93 to $73.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
50 Biggest Movers From Yesterday
Gainers
Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.